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Background: Health-related quality of life (HRQOL) and adherence to treatment are two
often inter-related concepts that have implications for patient management and care.
Tuberculosis (TB) and its treatment present a major public health concern in South Africa.
The study aimed to evaluate the association between HRQOL and adherence in TB
patients in South Africa.
Methods: Four self-reported HRQOL and one self-reported adherence measures were
used in an observational longitudinal multicentre study during 6-month standard TB
treatment. These included the generic Short-Form 12 items (SF-12) and EuropeanQuality
of Life 5 dimensions 5 levels (EQ-5D-5L), the disease-specific St. George’s Respiratory
Questionnaire (SGRQ) and the condition-specific Hospital Anxiety and Depression Scale
(HADS) for HRQOL. Adherence was measured by the Morisky Medication Adherence
Scale 8 items (MMAS-8). The relationship between both concepts was examined in 131
patients using Spearman’s rho correlations, and linear regression models.
Results: HRQOL improved over 6-month TB treatment, whereas adherence mean
scores stayed constant with participants attaining a medium average level. Around
76% of patients reported to be high adherers and 24% were reporting a medium or
low adherence. Associations between HRQOL and adherence were mainly weak. High
adherence at treatment start was positively related to improvements in anxiety and
depression after 6-month treatment. The overall improvement in pain and discomfort, and
psychosocial health aspects over treatment time was positively, but weakly associated
with adherence at 6 months of treatment.
Conclusion: A positive relationship exists between adherence and HRQOL in TB in a
South African setting, but this relationship was very weak, most likely because HRQOL
is affected by a number of different factors and not limited to effects of adherence.
Therefore, management of TB patients should, besides adequate drug treatment,
address the specific mental and psychosocial needs.
Keywords: quality of life, pulmonary tuberculosis, medication adherence, longitudinal study, patient-reported
outcomes
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INTRODUCTION
Both adherence and health-related quality of life (HRQOL) are
important indicators for the effectiveness and treatment success
of therapeutic interventions (Côté et al., 2003). Determinants of
adherence behavior are well-established in the literature (Kardas
et al., 2013). Psychosocial factors, such as poor levels of education,
have been shown to influence whether patients are adherent with
their medication. Treatment-related factors, such as complexity
(Pantuzza et al., 2017) and number of drugs (Sabaté, 2003), also
have a negative impact on adherence in many different chronic
conditions. It is expected that poor adherence leads to poorer
outcomes, including HRQOL, because if patients do not take
their prescribed medication, then it will have no therapeutic
effect. Treatment of tuberculosis (TB) is generally in two phases.
The first phase is an intensive phase typically combining four
drugs during 2 months. The second phase, involving two drugs
for 4 months, is often termed a continuous phase of treatment.
The complexity of TB treatment regime is a consideration for
adherence.
However, the association between HRQOL and adherence
to treatment has rarely been studied in tuberculosis (TB). Cote
et al. and Saleem et al. propose a model whereby HRQOL is
an ultimate outcome while adherence is seen as an intermediate
outcome (process variable). This model assumes that adherence
to therapeutic interventions drives changes in HRQOL occurring
with a delay (Côté et al., 2003; Saleem et al., 2012). However,
the relationship between the two concepts is complicated by a
possibility of reverse causality, i.e., a “backwards” influence of
HRQOL on adherence (Ágh et al., 2015). A systematic review
by Munro et al. identified two underlying mechanisms for the
association between well-being and adherence, specific to TB
treatment (Munro et al., 2007). The first mechanism relates to
TB patients prematurely stopping their treatment because they
feel better, and perceive the improvement in well-being as a
cure of TB. On the other hand, the second observed mechanism
refers to patients stopping treatment when they experience no
improvement or a worsening in their health status and well-
being, because they perceive the medication as not working
(Sabaté, 2003; Munro et al., 2007). This alternative model implies
that a change in HRQOL would appear first, and be followed by
a change in adherence behavior.
South Africa, which has the highest prevalence and incidence
rates of all 22 high-burden TB countries worldwide (WHO,
2016; Wang et al., 2017), has committed a significant portion
of its health budget to expand early detection and treatment
of TB (Christian, 2016; Kastien-Hilka et al., 2016; Dieleman
et al., 2017a; Jakovljevic et al., 2017). Aside from the financial
burden on the South African health budget, TB also places
a considerable burden on patients, significantly impacting the
physical, emotional, psycho-social and economic domains of
health (Dieleman et al., 2017b). Whilst available free of charge
in the public sector, a major challenge faced by the National TB
Programme and patients is the length and complexity of existing
treatment regimens. The incidence rate is slowly decreasing and
the relapse rate is high (WHO, 2016). These same domains are
known to impact medication adherence (Sabaté, 2003). The aim
of this research is to evaluate the relationship between patient-
reported HRQOL and adherence in pulmonary TB in South
Africa using a longitudinal study design. The evaluation of both
concepts over time allows identifying which health aspects of TB
have an influence on adherence and which health domains are
affected by non-adherence.
MATERIALS AND METHODS
Study Design
The study used an observational longitudinal design
including repeated measures of HRQOL and adherence. A
detailed description of the study design and methodology
has previously been published and briefly presented below
(Kastien-Hilka et al., 2016b).
Patient Population and Participant
Recruitment
Study participants were recruited between November 2014 and
May 2015 at six primary health care clinics with the highest TB
caseloads in Cape Town. The study population comprised of 131
patients newly diagnosed with active pulmonary TB who were
18 years of age or older. A detailed description of the study
population has been published elsewhere (Kastien-Hilka et al.,
2017). Of those who provided socio-demographic data (n= 129),
63.6% were man, 89.9% were black, the majority were between
20 and 40 years of age (46.5%), and 68.3% had high school
attainment. Just 26.6% of all participants reported currently being
employed or doing any kind of paid work.
Patients were excluded if they were diagnosed with multidrug-
resistant TB (MDR-TB), extensively drug-resistant TB (XDR-
TB), and/or had HIV co-infection. The eligibility status of each
patient was subject to verification by the nurse dedicated to TB
patients at each health facility. All enrolled participants signed a
written informed consent.
Study Procedures
Self-reported HRQOL data was collected at the beginning of the
6-month treatment period and at four follow-up visits (4, 8, 16
weeks and at the end of treatment) at each of the sites included in
the research. FourHRQOLmeasures and one socio-demographic
questionnaire were administered at baseline (treatment start).
These four HRQOL measures were administered again, together
with a self-reported adherence measure at the follow-up visits.
Adherence to medication data was collected during the follow-
up visits only, as no treatment was administered until after
baseline data were collected. Data were collected using paper
questionnaires during face-to-face interviews conducted by
trained field workers.
Study Material
The rationale for the selection of HRQOL measures and
adherence measure has been described previously (Kastien-
Hilka et al., 2016b). The self-reported questionnaires consisted
of; two generic quality of life questionnaires [Short-Form 12
items (SF-12; Jenkinson et al., 1997) and European Quality
of Life 5 dimensions 5 levels (EQ-5D-5L; Herdman et al.,
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2011)], one disease-specific quality of life questionnaire [St.
George’s Respiratory Questionnaire (SGRQ; Jones et al., 1992)]
and one condition-specific questionnaire [Hospital Anxiety
and Depression Scale (HADS; Zigmond and Snaith, 1983)].
Adherence to medication was measured using the Morisky
Medication Adherence Scale 8 items (MMAS-8; Morisky et al.,
2008; Krousel-Wood et al., 2009; Morisky and DiMatteo, 2011).
Statistical Analysis
All statistical analyses were conducted using IBM SPSS Version
23 R©. Descriptive analyses were applied to baseline socio-
demographic and adherence data by follow-up visit (N, %
missing, min, max, mean, SD, median and 95% Cis). Frequency
plots were also produced. Adherence data were also assessed by
levels of adherence (high adherence = 8; medium adherence =
6–<8; low adherence <6).
Longitudinal changes in adherence were examined by the
change in mean scores between follow-up visits. The change
in mean scores was assessed by paired-samples t-test at a 5%
significance level. Differences in adherence mean scores over
time were also examined using repeated measures ANOVA.
Bonferroni correction was applied to account formultiple testing.
The effect size partial eta squared (η2) was used to provide
information of the within-subject effect of time. Adjustments
were made for baseline level socio-demographic factors.
Associations between HRQOL and adherence mean scores
were examined using a step-wise method. First, relationships
between descriptive HRQOL and adherence measures were
explored. Second, Spearman’s correlation coefficients were
calculated between HRQOL domain-level and total mean scores
and adherence mean scores at each follow-up visit. Further,
Spearman’s correlation coefficients were examined between
changes in HRQOL mean scores (between baseline and both
follow-up visit 2 and follow-up visit 4) and adherence mean
scores at follow-up visit 4. Correlations >0.5 will be considered
as strong, between 0.3 and 0.5 as moderate, 0.1 and 0.3 as weak
and <0.1 as no correlation (Cohen, 1988). In a third step, linear
regression models were used to examine the associations over
time. Domain-based associations identified from the correlation
analysis were examined for confirmation.
Ethical Consideration
The study adhered to the International Conference on
Harmonisation of Technical Requirements for Registration
of Pharmaceuticals for Human Use (ICH) guidelines, the
Declaration of Helsinki and South African Good Clinical
Practice (GCP). The study was approved by the institutional
review commission of the Swiss Tropical and Public Health
Institute in Basel, the ethics committees of North-West and
Central Switzerland (EKNZ) and the University of Cape Town.
RESULTS
Development of HRQOL Over Time
Results from the self-reported HRQOL questionnaires revealed
significant impairment in overall HRQOL and domains at
baseline. Analyses identified socio-demographic determinants
associated with baseline HRQOL were age, education and work
status; where older, less educated and unemployed patients
report poorer HRQOL. Gender showed no significant effect
on HRQOL. HRQOL total and domain scores improved
over 6-month of TB treatment, with greatest improvement
observed during the intensive treatment phase. The changes in
HRQOL were statistically significant, and exceeded the published
thresholds for minimal important difference (MID) indicating
the differences can be interpreted as clinically meaningful. The
greatest improvement in HRQOL was observed in mental health
domain, such as anxiety and depression. Details have been
published recently (Kastien-Hilka et al., 2017).
Development of Adherence Over
Treatment Time
Table 1 and Figure 1 present self-reported adherence from 4
weeks (follow-up visit 1) to 6 months (follow-up visit 4)
of standard TB treatment. The mean MMAS-8 score for all
participants was in the range of medium adherence over all
time points. Based on the adherence grading of MMAS-8, the
TABLE 1 | Change in adherence over time (measured using the MMAS-8) by adherence level at first visit (Jenkinson et al., 1997)a.
Time since treatment start Mean change from
Visit 1, N
95% confidence
interval, Range
High adherers at first
visit (74%) Nb
Medium adherers at
first visit (19%), Nb
Low adherers at first
visit (7%), Nb
Week 4 (visit 1) (mean, SD [%]) 7.400 (1.474)
84
(7.076-7.716) 8.000
62
6.734
15
2.917
6
Week 8 (visit 2) +0.222
84
(7.394-7.851) −0.283
46
+0.991
10
+4.333
3
Week 16 (visit 3) +0.400
47
(7.601-7.995) −0.205
28
+1.266
5
+5.083
1
Week 24 (visit 4) +0.400
95
(7.089-7.701) −0.659
52
+0.691
10
+2.083
2
aMMAS-8 scores were not obtained during baseline (N = 131) as treatment had not commenced.
bAdherence was classified as “High” (MMAS-8 score=8), “Medium” (MASS-8 score = 6- <8) or “Low” (MASS-8 score<6).
Use of the ©MMAS is protected by US copyright laws. Permission for use is required. A license agreement is available from Donald E. Morisky, 14725 NE 20th St Bellevue, WA 98007;
dmorisky@gmail.com.
MMAS-8, Morisky Medication Adherence Scale 8 items; SD, standard deviation.
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FIGURE 1 | Absolute proportion of high, medium and low adherers (Top), and change of adherence over time, by adherence level at week 4, visit 1 (Bottom).
majority of TB patients reported high adherence at all follow-
up visits during treatment (74–89%), as shown in the top panel
of Figure 1. This high level of adherence remained unchanged
in most patients (79%) throughout the study period. However,
∼21% of patients classified as high adherers at follow-up visit 1
changed their adherence behavior to medium and low adherence
after 6 months (at follow-up visit 4). In the group of patients with
medium and low adherence, 46% improved their adherence to
high adherence behavior after 6 months of treatment. Adherence
at week 4 (follow-up visit 1) did not appear to be predictive
of adherence at later time points, as visible from Table 1 and
Figure 1 (bottom panel).
Age, gender and work status revealed no impact on adherence
at follow-up visits 1 and 4. Only education had a statistically
significant influence on the adherence at follow-up visit 4
(η2 = 0.129, P = 0.016). Specifically, at 6 months of treatment
a higher educational background was associated with lower
adherence scores. In a multivariate regression model retaining
non-significant effects of age, gender and work status, the
MMAS-8 score in persons with high school education was by
0.25 (P = 0.541) lower than in persons with primary school
education. It was by 1.71 (P = 0.011) lower in persons with
college or university education (P for the set of dummy variables
representing education, 0.027; value range of MMAS-8, 0-8).
Association between HRQOL and
Adherence Over Treatment Time
Figure 2 presents the association between HRQOL and level
of adherence (high, medium, or low), over all follow-up visits.
HRQOL improved significantly over the treatment time, while
overall mean adherence scores remained constant at a medium
adherence level. The most pronounced correlation identified
indicated a moderate and positive association between adherence
in the first 4 weeks (follow-up visit 1) and less problems in the
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FIGURE 2 | Association between HRQOL and adherence (high, medium or
low) over all follow-up visits using composite summary scores, Physical
Component Score (PCS), and Mental Component Score (MCS) of the SF-12.
Anxiety/Depression domain of the EQ-5D after 6 months of
treatment (follow-up visit 4; r = 0.430 P < 0.001). A similar
positive but weak relationship was observed between adherence
in the first 4 weeks (follow-up visit 1) and EQ-5D utility index
after 6 months of treatment (follow-up visit 1; r = 0.364 P =
0.003). After 6months of treatment (follow-up visit 4), a weak but
positive relationship between the SGRQ Symptoms and Activities
domains and adherence was observed (r = −0.297 P = 0.004;
r =−0.317 P = 0.002).
Spearman’s correlation was also calculated for overall
changes in HRQOL mean scores (baseline to follow-up visit
4) and adherence after 6 months of treatment. Statistically
significant, but weak correlations were observed with the overall
improvement of theHADSAnxiety (r= 0.226 P= 0.026), EQ-5D
Pain/Discomfort (r = 0.232 P = 0.026) and SGRQ Impacts (r =
0.291 P = 0.005) domains, and with the SGRQ total score (r =
0.226 P= 0.014). All these results indicated that an improvement
in HRQOL between baseline and follow-up visit 4 was positively
associated with higher adherence.
The multivariate model confirmed some of these
findings. It showed statistically significant, but very weak,
positive associations between improvements in the EQ-5D
Pain/Discomfort domain (η2 = 0.098 P = 0.041), SGRQ
Activities domain (η2 = 0.110 P = 0.026), SGRQ Impacts
domain (η2 = 0.131 P = 0.011) and SGRQ total score (η2 =
0.135 P = 0.013), and adherence at follow-up visit 4. The
associations between HRQOL domains and adherence were
responsible for 10–14% of the variance in the HRQOL domains.
In addition, an association between improvement of SGRQ total
score (η2 = 0.102 P = 0.039) in the first 8 weeks of treatment
(follow-up visit 2) and adherence at follow-up visit 4 was found;
this association accounted for 11% in the variance in SGRQ
total score. Patients with high adherence had a greater change in
HRQOL than patients with medium and low adherence. For the
SGRQ Activities and Impacts domains as well as for the SGRQ
total score, a worsening was observed for medium adherers.
The positive associations between overall improvements in
the EQ-5D Pain/Discomfort domain (η2 = 0.071 P = 0.038),
SGRQ Impacts domain (η2 = 0.088 P = 0.015) and SGRQ total
score (η2 = 0.077 P = 0.031), and adherence after 6 months of
treatment (follow-up visit 4) from the multivariate model were
further confirmed by statistically significant results from repeated
measures ANOVA.
Whilst no significant relationships between HRQOL and
adherence levels were found during the intensive treatment
phase, the above-described associations were confirmed for the
continuous treatment phase. During the continuous treatment
phase, there were significant and positive associations between
HRQOL and adherence, with an effect size of 10–15%, related
to the EQ-5D Pain/Discomfort domain (η2 = 0.103, P = 0.032),
EQ-5D VAS (η2 = 0.156 P = 0.004), and SGRQ Activities (η2
= 0.123, P = 0.015) and Impact domains (η2 = 0.124 P =
0.014). High adherers reported a greater change in HRQOL than
low adherers. Medium adherers showed a worsening in HRQOL
during the continuous treatment phase in the SGRQ Impacts and
Activities domains (Table 2).
DISCUSSION
Despite treatment complexity being a predictive factor for
low adherence in other conditions, the results of this study
demonstrate that adherence to TB treatment within South Africa
was high, and remained high throughout both the intensive and
continuous treatment phases. The study showed that HRQOL
improved in all domains, and that adherence behavior was
constant, with most patients being classified as high adherer’s
during the course of 6-month standard treatment. Amongst
baseline characteristics, only education had a significant effect
on adherence after 6 months of treatment, with patients with
lower education reporting better adherence. These patients also
had lower HRQoL at baseline (Kastien-Hilka et al., 2017).
Associations between HRQOL and adherence were statistically
significant, but mainly weak. Generally, there were positive
associations between adherence during the first four weeks of
treatment and good HRQOL after 6 months of treatment in
terms of lower levels of anxiety and depression and overall
HRQOL. This would suggest that higher levels of adherence
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TABLE 2 | Associations between HRQOL and adherence during the intensive and continuous treatment phases.
HRQOL Spearman’s rho correlation
(HRQOL and adherence at 6
months of treatment) r
(P-value)
Spearman’s rho correlation
(changes in HRQOL;
adherence at 6 months) r
(P-value)
Univariate model for
continuous
treatment phase η2
(P-value)
Multivariate model
(changes in HRQOL;
adherence at 6
months) η2 (P-value)
Repeated
measures
ANOVA η2
(P-value)
EQ-5D
Pain/Discomfort
0.232
(P = 0.026)
0.103
(P = 0.032)
0.098
(P = 0.041)
0.071
(P = 0.038)
SGRQ Activities −0.317
(P = 0.002)
0.123
(P = 0.015)
0.110
(P = 0.026)
SGRQ Impacts 0.291
(P = 0.005)
0.124
(P = 0.014)
0.131
(P = 0.011)
0.088
(P = 0.015)
Significance level, 0.05. HRQOL, health-related quality of life; ANOVA, analysis of variance; EQ-5D, European Quality of Life 5 dimensions 5 levels; SGRQ, St. George’s Respiratory
Questionnaire.
may positively influence the improvements in psychological
distress. Our study did not find associations between HRQOL
at treatment start and adherence over treatment time. However,
other studies reported that an impaired HRQOL at treatment
start negatively impacted adherence in patients with chronic
obstructive pulmonary disease (COPD; Ágh et al., 2015).
Psychological distress, including anxiety and depression, are
reported to be prevalent in TB patients (Kastien-Hilka et al.,
2017). Theron et al. assessed psychological distress in TB patients
in Southern Africa and observed a significant relationship
between higher levels of TB-related psychological distress and
non-adherence (Theron et al., 2015). In our study, depression
at treatment start did not appear to be a trigger for reduced
adherence. Rather, high adherence to treatment appeared to
improve anxiety and depression.
LIMITATIONS
The study is not without limitations. Combined generic
with disease- and condition specific HRQOL measures were
administered to ensure that all possible, relevant HRQOL
domains were captured. However, there is no specific TBHRQOL
measure. Generic measures such as SF-12 and EQ-5D may not
be sensitive enough to examine associations with adherence. The
EQ-5D is a preference-based instrument designed to only react
to substantial changes in overall HRQoL. Given this, it may
not be surprising that, in the multivariable analysis, we could
confirm associations between adherence and individual EQ-5D
domains, but not the overall EQ-5D utility index. We used
a self-reported measure of adherence that may have impacted
on the reliability of the observed relationship between HRQOL
and adherence. An ideal adherence measure would assess
overall adherence to medication including initiation, persistence,
implementation and discontinuation. However, such a measure
does not exist (Fairman and Motheral, 2000; Nguyen et al.,
2014).
We were not able to look at the relationship between each
of the adherence groups (high, medium, and low) and clinical
outcomes for each of the patients who participated in this
study. Further research would be required to examine adherence
levels and clinical outcomes, perhaps using the sputum smear
microscopy test to assess levels of TB bacteria.
Finally, for unknown reasons, the response rate at the follow-
up visit 3 (after 16 weeks of treatment) was very low (Table 1).
However, only few analyses made use of the date for this time
point, such that a substantial impact on the overall results appears
unlikely. The groups of medium and low adherers at the first
follow-up visit were very small and subsequent assessments (for
follow-up visits 2–4) performed in these groups were additionally
affected by missing values.
CONCLUSIONS
Very few studies have evaluated the association between
different HRQOL aspects and adherence to treatment. Gaining
a better understanding of adherence-related issues is a crucial
step toward improving health outcomes and lowering health
care costs. This study adds to the growing evidence for
treatment adherence in TB patient populations specific to
South Africa. A positive relationship exists between adherence
and HRQOL in TB in a South African setting, but this
relationship was very weak, most likely because HRQOL is
affected by a number of different factors and not limited to
effects of adherence. Therefore, management of TB patients
should, besides adequate drug treatment, address their specific
mental and psychosocial needs. Such integrative patient-centered
approach could result in an improvement in the quality of life of
these patients.
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